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Protocol
AbstrACt
Introduction Attention-deficit hyperactivity disorder 
(ADHD) has been related to increased rates of 
unintentional injuries. However, the magnitude of the 
effect and to which extent variables such as sex, age or 
comorbidity can influence this relationship is unknown. 
Additionally, and importantly, it is unclear if, and to which 
degree, ADHD medications can decrease the number of 
unintentional injuries. Due to the amount of economic 
and social resources invested in the treatment of injuries, 
filling these gaps in the literature is highly relevant from a 
public health standpoint. Here, we present a protocol for 
a systematic review and meta-analysis to estimate the 
relationship between ADHD and unintentional injuries and 
assess the impact of pharmacological treatment for ADHD
Methods and analysis We will combine results from 114 
bibliographic databases for studies relating ADHD and 
risk of injuries. Bibliographic searches and data extraction 
will be carried out independently by two researchers. The 
studies’ risk of bias will be assessed using the Newcastle-
Ottawa Scale. Articles reporting ORs or HRs of suffering 
an injury in ADHD compared with controls (or enough 
data to calculate them) will be combined using Robust 
Variance Estimation, a method that permits to include 
multiple non-independent outcomes in the analysis. 
All analyses will be carried out in Stata. Age, sex and 
comorbid conduct disorders will be considered as potential 
causes of variance and their effect analysed through 
meta-regression and subgroup analysis. Sensitivity 
analyses will exclude articles with longer follow-ups, non-
stringent definitions of ADHD or controls and statistically 
uncontrolled/controlled outcomes. Studies implementing 
a self-controlled case series methodology to investigate if 
ADHD drugs reduce the risk of injuries will be combined 
with a generalised linear mixed model using the Poisson 
distribution and a log link function.
registration details PROSPERO—Prospective Register of 
Systematic Reviews (CRD42017064967)
IntroduCtIon
unintentional injuries in childhood
According to WHO, injury can be defined 
as, 'The physical damage that results when a 
human body is suddenly subjected to energy 
in amounts that exceed the threshold of 
physiological tolerance or else the result of a 
lack of one or more vital elements, such as 
oxygen'.1 Therefore, unintentional injuries 
in children and young people (CYP) include 
traffic injuries, drowning, poisoning, falls or 
any other traumatic injury and burns.
Childhood unintentional injury is a major 
cause of death and disability among children 
and adolescents: over 5 00 000 children die 
worldwide every year from unintentional inju-
ries and many more are left with permanent 
strengths and limitations of this study
 ► Search and data extraction conducted independently 
by two authors in three major databases (PubMed, 
Scopus, Web of Science) and a results aggregator 
searching simultaneously in 113 databases, without 
time or language limitations.
 ► Analytical plan including two different meta-
analyses aimed at answering two different but 
related questions: risk of injuries in attention-
deficit  hyperactivity disorder  (ADHD) and possible 
protective role of ADHD drugs for this risk.
 ► Clinical importance of answering whether ADHD 
medications have a significant influence on the risk 
of injuries.
 ► Usage of Robust Variance Estimation: a recent 
statistical methodology that permits the combination 
of non-independent outcomes.
 ► It is expected that the scope of this review will 
be limited by the number of studies reporting the 
relationship between medication for ADHD and risk 
of injuries.
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disabilities.1 Injuries are especially relevant in childhood 
compared with adulthood. Developmental factors make 
CYP more prone to unintentional injuries compared with 
adults. Additionally, their anatomical fragility, smaller size 
and brain immaturity lead to more serious injuries and 
sequelae.2 Injury risk varies by sex, with a higher risk in 
males. It also varies with age. According to the WHO 2008 
report on child injury prevention,1 in high-income coun-
tries children under 1 year and over 15 years have greater 
risks of death from unintentional injuries (28 and 23.9 
death rates per 1 00 000, respectively). Socioeconomic 
deprivation is an additional factor associated with the 
probability of unintentional injury. Rates (per 100 000) of 
estimated mortality due to unintentional injuries in CYP 
in high-income countries were 12.2 as opposed to 41.7 
in low-income and middle-income countries in this same 
report by WHO.1
Moreover, CYP from families from low socioeconomic 
areas have a higher incidence of unintentional injuries 
compared with those less deprived,1 for example, a study 
found that across England rates of serious injury in chil-
dren as pedestrians were higher in the most deprived 
areas than in the least deprived (rate ratio (RR) 4.1; 
95% CI 2.8 to 6.0 domestic product).3 As a result of 
the higher incidence of unintentional injuries in more 
economically deprived CYP, there is a contribution to 
ongoing inequalities between children within nations 
and comparing children from different nations.
There is little evidence on the evidence of the economic 
costs of injuries as a proportion of gross domestic product 
globally. However, acute treatment costs of unintentional 
injuries sum €4000 million worldwide every year,4 whereas 
the National Health Service in the UK calculated that the 
extra cost of healthcare of injured children compared 
with non-injured children was €45 million.5 The injuries 
that occurred in the year 2000 in CYP under the age of 
14 years from the USA will have an estimated lifetime 
cost from medical treatments of US$11 899 million and 
US$38 664 million from lost productivity.6
Importantly, an issue that makes unintentional injuries 
an even bigger healthcare priority is the fact that most 
of the times their consequences could be prevented or 
minimised with the proper educational, legal or environ-
mental measures. In fact, injuries are the first preventable 
cause of death and disability.5
Attention-deficit hyperactivity disorder
Attention-deficit hyperactivity disorder (ADHD) is the 
most common neurodevelopmental disorder, with 
an estimated worldwide prevalence between 3% and 
5% among children and adolescents, being three to four 
times more prevalent in males than females.7–9 The most 
recent version of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5), defines ADHD as a disorder 
characterised by a persistent pattern of hyperactivity/
impulsivity and/or inattention, affecting both develop-
ment and functioning. The symptoms need to be present 
in at least two settings and influence negatively academic, 
occupational or social activities from childhood to adult 
life.10
The economic burden of ADHD is very high. Health-
care spending in patients with ADHD has been estimated 
to be between US$600 and US$2000 greater than for 
an individual without ADHD.11 12 Importantly, a signifi-
cant part of such increase in healthcare expenditure is a 
direct consequence of the higher likelihood of injuries 
in individuals with ADHD.13 The relationship between 
ADHD and the risk of unintentional injuries has been 
widely studied.14 15 However, available studies present with 
caveats and sample sizes and study methods have differed 
significantly across studies. Case-control studies are the 
most frequent in the literature, but, quite often, they 
assessed only one type of injuries such as dental,16 frac-
tures of specific body bones17 or burns.18 An important 
limitation of this type of studies is that they have typically 
relied on a small sample size, which hinders the statistical 
control of confounding factors that could be leading to a 
spurious correlation between ADHD and unintentional 
injuries. Nevertheless, studies tend to show a higher inci-
dence of injuries in ADHD CYP. Longitudinal cohort 
studies have also been conducted on the relationship 
between ADHD and physical injuries. Although few in 
number, they included large sample sizes, hence permit-
ting an increased statistical rigour. Estimates of the differ-
ences have varied greatly between studies. In a large 
sample, Rowe et al found an OR of 1.6 (95% CI 1.6 to 2.3) 
for a statistically significant increased risk of fractures in 
ADHD compared with controls, while others have found 
ORs over 3.19–21
Furthermore, comorbidity with oppositional defiant 
disorder (ODD) and conduct disorder (CD) has been 
related to an increased risk of unintentional injuries 
in some studies, so that it could be argued that both 
disorders, highly comorbid with ADHD, could play a 
major role in the relationship between ADHD and unin-
tentional injuries. However, while a recent European 
study with a total sample of 4517 individuals found no 
differences between children with ADHD and controls 
(OR 0.91, 95% CI 0.56 to 1.48) when comorbidity and 
other variables were controlled for,22 another study found 
a similar risk of injuries when ADHD with conduct prob-
lems were compared with controls than when ADHD 
without conduct problems were compared with controls 
(OR close to 1.5).23 Another factor that could contribute 
to the differences in the risk estimation between studies 
could be an interaction between diagnosis and variables 
that influence the risk of injuries in the general popula-
tion, namely age and sex.
Summarising, while there is evidence supporting a 
higher risk of injuries in ADHD CYP, the magnitude of 
the difference remains unclear. Additionally, to which 
extent variables such age and sex which could influence 
the possible association deserve further investigation.24 
Finally, the suggestion that comorbidity with ODD and 
CD25 could lead to a higher risk of unintentional injuries 
needs to be more rigorously tested.
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unintentional injuries and AdHd medication
ADHD medications are effective for treating symptoms 
and improving academic achievement, at least in the 
short term.26 27 There is evidence to suggest that the use 
of ADHD medication in children and adolescents could 
be associated with a reduced risk of drug abuse and crim-
inality.28–30 ADHD medication may also reduce the risk of 
unintentional injuries, but results are inconsistent across 
studies.31–34
Estimating and interpreting the effect of medication is 
not straightforward. For example, patients who receive 
medication could have more severe ADHD symptoms 
and, hence, they could have an increased risk of uninten-
tional injuries.35 Recent methodologically sound studies 
have taken advantage of the short half-life of stimulants 
and used it to compare the risk of accidents of individuals 
when taking the medication compared with themselves 
when not taking it. This statistical method is known as 
self-controlled case series and allows the control for all 
time time-invariant individual confounders (including 
sex, socioeconomic background and more importantly, 
severity of symptoms).36 Importantly, the self-controlled 
case series methodology (SCCS from now on) requires 
that all study subjects have suffered at least one outcome 
(injury in our case) of interest. This, combined with the 
fact that unintentional injuries are not highly frequent, 
leads to the need of very large sample sizes to confidently 
estimate whether medication influences the risk of inju-
ries. The first study using the self-controlled case series 
design in ADHD had a sample size of 328 individuals with 
ADHD who had suffered an injury and found a protective 
effect of medication only for male adolescents.31 Simi-
larly, Mikolajczyk et al found a protective effect only for 
the risk of traumatic brain injuries in a sample of 2128 
injury cases among individuals with ADHD, whereas a 
more recent study with over 4000 patients concluded 
that medication decreases the risk of unintentional inju-
ries.37 Whereas the effect of medication on the risk of 
injury could theoretically only be rigorously assessed in 
randomised controlled trials, practical constraints associ-
ated with this design make them unsuitable to test the 
effect of a possible protective effect of medication on risk 
of injuries in the long term.
The short-term and long-term effects of medication 
should be taken into account when weighting the clin-
ical decision of prescribing drugs for ADHD. A possible 
protective effect of ADHD medications on unintentional 
injuries could be an additional key factor to be consid-
ered when assessing the possible benefits and harms 
of the pharmacological treatment for ADHD. Gaining 
insight into the effects of ADHD drugs on injuries may 
have important implications for the day-to-day clinical 
practice. For instance, a sizeable number of practitioners 
recommend stopping medication during school holiday 
periods. Assuming that ADHD drugs do have a protec-
tive effect on the occurrence of injuries, such practice 
should be discouraged, at least in individuals with ADHD 
at higher risk (eg, adolescents).
Due to the high prevalence of ADHD, and the fact that 
unintentional injuries represent a source of major impair-
ment for society as a whole, decreasing the risk of injuries 
in ADHD should be a public health priority.
In view of the inconsistencies in the literature and 
the significance of this research, a systematic review and 
meta-analysis on the differential risk between individuals 
with and without ADHD and on the effect of medications 
will allow to provide meta-analytic support to address 
these important gaps in the literature. Results will directly 
inform clinical practice and healthcare planning.
We note that during the final stages of the prepara-
tion of this manuscript (and after our protocol had been 
registered in Prospective Register of Systematic Reviews 
(PROSPERO)), a systematic review and meta-analysis on 
the risk of injuries in ADHD was published by Amiri et 
al,38 showing a significant association between ADHD and 
risk of injuries (pooled OR 2.04 (95% CI 1,59 to 2,63)). 
We deem that the present systematic review/meta-analysis 
expands and complements the work by Amiri et al in a 
number of ways. First, the bibliographic searches in Amiri 
et al were conducted for articles published between 2000 
and 2014. Of note, in the last 3 years there has been a 
surge of high-quality articles relevant for our meta-anal-
ysis. Second, we aimed to control for gender effects, an 
important confounder. Third, and perhaps more impor-
tantly, we address a very relevant clinical and public 
health question, namely the effect of ADHD drugs on the 
risk of injuries. Finally, the fact that the current project 
is registered and follows reporting guidelines (including 
the publication of the protocol) should give further 
confidence in the precision of its results. For all these 
reasons, we believe that the current meta-analysis will 
help to advance our current understanding of ADHD and 
contribute to build the evidence for programmes aiming 
to prevent unintentional injuries in CYP.
HypotHesIs And objeCtIves
The overarching aim of the study will be to assess the 
degree of association between ADHD and unintentional 
physical injuries and to estimate the impact of the phar-
macological treatment of ADHD on the association.
Main review questions and hypothesis
1. Is the risk of unintentional physical injuries 
significantly higher in children and adolescents 
compared with those without ADHD?
We hypothesise that children and adolescents with 
ADHD will have a significantly higher probability of 
suffering an unintentional injury compared with indi-
viduals without ADHD.
2. Do ADHD medications affect the risk of unintentional 
injuries in ADHD individuals?
Our research hypothesis is that the pharmacological 
treatment of ADHD symptomatology significantly de-
creases the risk of unintentional injuries.
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Additional review questions
Do age, gender and psychiatric comorbidities (ODD or 
CD) moderate differences in the risk of unintentional 
physical injuries in individuals with versus individuals 
without ADHD?
Our hypothesis is that comorbid behavioural disor-
ders (ODD or CD) will increase the risk of unintentional 
injuries. However, we predict that the increased risk of 
injuries will still be significant after controlling for these 
comorbidities. Additionally, it has not been previously 
tested if there is an interaction between age or sex and 
diagnosis in relation to the risk of injuries and we do not 
have a priori hypotheses on the effect of this interaction.
MetHods
We will follow healthcare and epidemiology meta-an-
alytic research guidelines, namely: 1) the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA,39 40), a 27-item checklist and associated 
information that includes aspects deemed essential for 
transparent reporting of a systematic review, and its coun-
terpart for the reporting of protocols (PRISMA-P41 42) and 
2) the Meta-Analysis of Observational Studies in Epide-
miology,43 a framework highlighting the specificities of 
meta-analysing population-based studies.
eligibility criteria
Participants/population
The population to be studied will consist of children and 
adolescents with ADHD aged <18 years. The presence 
of ADHD will be defined operationally as one of the 
following:
1. A categorical diagnosis according to standardised 
criteria, either the DSM (III, III-R, IV, IV-TR or 5) 
or the diagnosis of hyperkinetic disorder as per 
International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10) or 
previous versions.
2. A positive answer to the question: ‘Have you ever been 
told that you have ADHD by a doctor?'
3. Being prescribed ADHD medication(s).
4. Being above a pre-established threshold in a validated 
psychometric scale for the screening of ADHD symp-
toms. This threshold can also be a percentile of the 
sample. Studies in which the severity of ADHD symp-
toms is related to injuries, but no explicit diagnostic 
threshold is used, will not be included.
5. ADHD-related codes in medical, healthcare or 
administrative registries.
Operational definitions #1–3 have been designed to 
include articles identifying children with clinically known 
or recorded ADHD diagnoses. Operational definitions 
#4–5 have been chosen to include articles that evaluate 
ADHD in community studies or healthcare systems.
Studies will be included regardless of medication status 
(specific medications for ADHD or any other medication) 
or sex ratio. Comorbidities (psychiatric or other) in all 
or part of the study participants will not be exclusionary. 
Studies including only preschool children will not be eligible 
as diagnosis at this age range is controversial. Studies based 
on the diagnosis of deficits in attention, motor control and 
perception,44 or equivalent constructs,45 will not be included 
as the motor control problems required for their diagnosis 
and not needed in the case of ADHD diagnosis could be 
related to specific kinds of injuries or a different incidence 
of them, hence adding an extra source of variability.46
Intervention(s), exposure(s)
As the first part of this meta-analysis evaluates the risk of 
unintentional injuries in patients with ADHD compared 
with controls, no intervention will be assessed.
Regarding our second research question, we aim to 
evaluate the impact of any ADHD medication (ie, inter-
vention) on the incidence of injuries and hence, we will 
be comparing only patient samples. ADHD medication 
intake will be defined as the medical advice for taking a 
drug containing dextroamphetamine, methylphenidate 
or atomoxetine as included in a medical registry, or the 
purchase of these compounds. To be included in this 
analysis, studies will have to compare the risk of injuries 
during periods with and without medication. Studies 
comparing the incidence of injuries in groups of medi-
cated and unmedicated patients will be excluded since 
medication usage is related to confounding variables for 
our research question, such as symptoms severity.35
unintentional injuries
The WHO definition of unintentional injuries will be 
followed to decide inclusion of articles. Hence, articles 
reporting injuries covered with the codes S00-T98 of the 
19th chapter of the ICD-1047 will be deemed eligible. An 
exception will be studies specifically on traumatic brain 
injury (TBI) or concussions. These will not be included 
in the systematic review as they may introduce bias, since 
traumatic brain injury can increase attentional and impul-
sivity problems, as well as the risk of an ADHD diagnosis.48 
Studies on intoxications will not be included either, 
as results would probably be influenced by the greater 
access of individuals with ADHD to medications and not 
the intrinsic characteristics of ADHD.49
We will include studies where injuries were documented 
in a medical setting, reported through medical registries, 
recorded in medical histories or self-reported. Articles 
in which the injuries were self-induced will be excluded. 
Examples of the latter type of injury include self-mutila-
tion and fight-related injuries.
Studies in which individuals suffered an uninten-
tional injury before being diagnosed will be included. 
Indeed, there is no reason to suspect a temporal rela-
tionship between injuries and diagnosis once TBI studies 
are omitted. Finally, studies reporting risk of injuries in 
general, that is, without discriminating between inten-
tional or unintentional injury, will be included in the 
meta-analysis, as the majority of injuries in children or 
adolescents are expected to be unintentional in nature.
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Controls
We will define controls as children and adolescents under 
the age of 18 without ADHD. Specifically, we will include 
as controls: 1) individuals recruited from samples thought 
to represent the general population that do not have 
any psychiatric or neurological disorder, 2) individuals 
thought to represent the general population that do not 
have ADHD but could have other psychiatric or neurolog-
ical disorders or 3) individuals who were recruited specif-
ically from other clinical populations other than ADHD 
that a priori were not judged by the study authors to be 
related to an increased risk unintentional injuries.
types of studies to be included
We will pool the results from any published or unpub-
lished study that contrasts unintentional injuries in 
children or adolescents with ADHD and in typically devel-
oping individuals (meta-analysis of risk), or alternatively 
in patients with ADHD while taking and not taking medi-
cation (meta-analysis on the effect of medications, which 
will compare time points with or without medication). 
Empirical papers that include statistical analyses (ie, typi-
cally not reviews, letters, commentaries and editorials) 
with any kind of design will be accepted (mainly cohort 
studies, case and controls and cross-sectional studies but 
also clinical trials). Any temporality of the design (ie, 
prospective, retrospective or cross-sectional) or setting 
(clinical or general population) will also be accepted.
It is well known that the risk of unintentional injuries 
is highly related to male gender. Similarly, ADHD diag-
nosis is fourfold more prevalent in males. Any outcome 
derived from a control and ADHD sample with a different 
proportion of sexes between them that is not statistically 
controlled will be doomed to show an spuriously high risk 
of injuries in the ADHD group due to this co-correlation. 
Therefore, we will only include studies that control for sex 
differences between individuals with ADHD and controls 
either by sample selection or statistically. It must be noted 
that the meta-analysis by Amiri et al did not take into 
account this confounder when selecting their outcomes 
and this could be yielding higher estimates of risk.38
When evaluating medication effects, only studies using 
a SCCS methodology will be included a priori.31 Studies 
that controlled for individual differences between the 
medicated and unmedicated groups with different tech-
niques than the SCCS will be judged on a case-by-case 
basis for inclusion in a secondary comparison aimed at 
evaluating the robustness of the main comparison in 
addition to SCCS studies. This could include randomised 
controlled trials, studies comparing a short period before 
and after starting medication usage or other designs not 
foreseen.
We will not limit the inclusion for papers to any specific 
language.
Information sources
Electronic searches will be performed separately in the 
following databases:
 ► PubMed (Medline Plus)
 ► Scopus
 ► Web of Science Core Collection
A similar search will be carried out in UNIKA (http://
www. unav. edu/ en/ web/ biblioteca), an institutional refer-
ence aggregator that uses the EBSCO discovery service 
(http:// support. ebsco. com/ help/ index. php? lang= en& 
int= eds) to provide a combined list of references from 
both internal (library) and external (database vendors) 
sources. For a list with the 113 most important databases 
for medical research scoped through this service see the 
online supplementary file. We will perform searches in 
these databases from their inception to date without 
limiting the type of study, language or year. Addition-
ally, the International Clinical Trials Registry Platform 
Search Portal and  ClinicalTrial. gov will be checked to 
find ongoing or recently ended trials and, conversely, 
PROSPERO will be searched for ongoing or recently 
completed systematic reviews. Once the electronic search 
is completed, references from each pertinent paper will 
be checked in order to find out if there are any rele-
vant studies which had been missed during the database 
searches.
search strategy
The following search syntax will be used to find relevant 
terms in reference titles, abstracts or keywords (any field 
in the case of Medline-PubMed). Search terms and syntax 
will be adapted for each specific database: all the different 
searches can be found in the online supplementary file.
(ADHD OR adhd OR attention deficit disorder with 
hyperactivity OR syndrome hyperkinetic OR hyperkinetic 
syndrome OR hyperactivity disorder OR hyperactive 
child syndrome OR childhood hyperkinetic syndrome 
OR attention deficit hyperactivity disorders OR attention 
deficit hyperactivity disorder OR adhd attention deficit 
hyperactivity disorder OR adhd OR overactive child 
syndrome OR attention deficit hyperkinetic disorder 
OR hyperkinetic disorder OR attention deficit disorder 
hyperactivity OR attention deficit disorders hyperactivity 
OR child attention deficit disorder OR hyperkinetic 
syndromes OR syndromes hyperkinetic OR hyperkinetic 
syndrome childhood) AND ((fracture OR fractures OR 
traumatism OR traumatisms OR traumatology OR wound 
OR wounds OR drowning OR poisoning OR burning) OR 
((trauma OR traumat* OR harm OR lesion OR lesions 
OR injury OR injuries) AND (emergency OR emergency 
visit OR emergency room OR hospital OR hospitaliz* OR 
er OR inpatient))).
The whole process of article selection will be presented 
in a diagram following the PRISMA guidelines.
outCoMes
primary outcomes
Our primary outcome measure will be the OR of ADHD 
individuals suffering unintentional injuries that are eval-
uated at a medical setting (primary care doctor or any 
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other type of medical professional, emergency room 
or specialist care) compared with individuals without 
ADHD. The OR is the most common reported measure 
and the only one that can be obtained when comparing 
the number of individuals with ADHD in an injured 
sample to a non-injured group. The variable ‘injuries’ 
will have to be described dichotomously, that is, whether 
an individual has suffered an injury or not. If OR is not 
directly reported in the paper, but data to calculate it are, 
we will determine the OR for that particular study.
Since more than one injury can occur in one individual, 
the use of Cox Proportional Hazards Models is desirable 
since HR estimate the rate to injuries and are indepen-
dent of the time of follow-up. Whereas this kind of studies 
is rare, we will additionally evaluate the average effect size 
of studies reporting HR outcomes.
In the case of the meta-analysis evaluating the efficacy 
of ADHD medication, the primary outcome will be the 
incident rate ratio (IRR) obtained from SCCS studies. 
The incident rate is a measure of event frequency during 
a period of time. It is defined as the count of events 
divided by the observed person-time. The IRR is a rela-
tive measure which consists of dividing the incident rates 
of two different conditions. We will specifically compare 
injury occurrence among subjects with ADHD when 
medicated to the periods without medication, taking 
into account the fact that the time on medication varies 
between subjects. The number of events (injuries) and 
the person-time at risk during the periods with and 
without medication will be needed for its calculation.
If effect measures other than OR, HR (from Cox 
models) or IRR are reported, and OR (or IRR for the 
medication case) cannot be calculated from the data in 
the studies, the authors will be contacted to gather rele-
vant data.
Identification and selection of studies
Studies identified with electronic and manual searches 
will be listed with citation, titles and abstracts in Mendeley 
(Elsevier, New York) and duplicates will be excluded both 
using the function ‘delete duplicates’ of Mendeley and 
manually removing duplicates not discarded automati-
cally. Members of the review team will be trained in soft-
ware utilisation before starting the review.
Article screening against inclusion criteria will be 
carried out independently by two of the authors (MR and 
GA), who will try to reach consensus in case of discrep-
ancies between them. A third author (SC) will arbitrate 
in the final decision whenever consensus is not reached.
There will be two stages in the articles selection process:
 ► The title and abstracts of all non-duplicated papers 
will be screened, and studies that clearly do not fulfil 
the inclusion criteria will be excluded from further 
analysis. If the two evaluators disagree in their ratings, 
articles will be moved forward to the next phase.
 ► All text of articles remaining from the previous 
screening will be downloaded. Eligibility will be judged 
following the same scheme than during the previous 
phase: the same two authors will independently eval-
uate the studies for eligibility and seek comments 
from a third author in case of discrepancy.
As studies may sometimes be published as several 
reports, we will actively search for duplicate reporting of 
studies, taking into account as main indicators location 
of the study, authors and year. Whenever a study includes 
data from multiple reports, they will be linked in the data 
extraction sheet and data from the largest sample, when 
possible, will be used. In the case of prospective studies, 
only baseline data will be analysed. Corresponding 
authors of the original studies will be contacted to clarify 
article eligibility if necessary.
A list of excluded studies will be provided with reasons 
for exclusion. This list will include all articles that were 
preliminarily retained after stage 1 (selection from title 
and abstract) but finally excluded in stage 2.
data extraction
All articles considered appropriate in the previous stage 
will be read and analysed by at least two independent 
authors (one will always be MR or GA), who will extract 
the key information and include it in a Microsoft Excel 
document, with a third author acting as an arbitrator 
when consensus on discrepancies is not reached (SC). 
This phase will be first piloted with a small number of arti-
cles. The Excel file will have as many drop-down lists as 
possible to maximise inter-rater reliability, and also space 
for notes. Moreover, it will also include in-cell messages 
with help texts. A training session will be provided for all 
researchers involved in data coding.
Data on publication and data extraction details will be 
inserted in an excel sheet as follows: first author, journal, 
year of publication, country(ies) where the study was 
conducted and a more specific location such as region or 
hospital when applicable, final checking of fulfilment of 
inclusion and exclusion criteria and date and author of 
data extraction.
The description of the study design will include type 
of study (cross-sectional, case-control, cohort or clinical 
trial); temporal sequence (prospective, retrospective or 
cross-sectional, duration of follow-up, participants enrol-
ment (consecutive, non-consecutive); setting (clinical vs 
epidemiological population study) and year in which data 
acquisition for the study was carried out.
Regarding participant details, we will code sample 
size, age, gender distribution, ethnicity and sociodemo-
graphic status, characteristics of participants without 
ADHD (no ADHD, no ADHD or other conditions or 
comparisons with other diagnostic categories other than 
ADHD); psychiatric comorbidities of individuals with 
and without ADHD (type and prevalence); method to 
establish the diagnosis of ADHD (self-reported diag-
nosis, diagnosis recorded in medical files/registry, struc-
tured or semi-structured interview according to DSM or 
ICD, questionnaires, per medication usage or positive 
answer to the question: "Have you ever been told you 
have ADHD?"); medication status of individuals with and 
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without ADHD (type of medication and percentage of 
treated participants).
The primary outcome will be the OR (or HR)  of 
suffering an unintentional injury in individuals with 
ADHD versus children and adolescents without ADHD. 
In relation to outcomes, data that will be coded include 
treatment setting (acute care hospitals, emergency 
facilities, general practice, medical specialist or other, 
including extended care facilities such as nursing homes, 
offices, schools and communities), method to document 
injuries (registry, acute treatment, through expert retro-
spective analysis or self-report), type of injury (trauma-
tology, traffic injuries, drowning, poisoning, burns and 
chemical, other unintentional, self-induced, any kind of 
accidental injury or any kind of injury) and body location 
of the injuries.
To obtain ORs, any numeric data (raw number of acci-
dents in each of the samples or ORs and their CIs) will 
be coded including both unadjusted analyses and anal-
yses adjusted for covariates. In the latter case, covariates 
will also be included in the data extraction sheet. Finally, 
the reporting of any subgroup analysis or comparison of 
interest, the presence of other intervention groups and 
the main conclusions of the reports will also be annotated.
Whether the incidence of unintentional injuries differs 
between individuals with ADHD with medication and 
patients with ADHD without it will be assessed in a second 
meta-analysis. The data extraction sheet used for this 
second analysis will have the same variables and coding, 
but IRR instead of OR will be used.
We will extract information on multiple outcomes 
per article. Specifically, outcomes from different age or 
gender groups, multiple control groups, varying diagnosis 
techniques or statistical models will be valid. We will not 
include outcomes differentiating by injured body part. 
Each outcome or comparison will all be included in the 
spread sheet using a different line. A different compar-
ison ID will be used in such case in combination with a 
report and study ID to link all related data.
Assessment of study quality and bias in included studies
The evaluation of study quality and possible bias will be indi-
vidually performed by two researchers for each article. As 
there is no agreement about the best method to evaluate 
study quality in meta-analyses of observational studies, we will 
use an adapted version (included in the online supplemen-
tary file) of the Newcastle-Ottawa Scale,50 which has been 
used in several previous meta-analyses51 52 and is reviewed 
in the Cochrane Handbook. This scale evaluates the sample 
selection methods, the comparability among studied groups 
and the ascertainment of either the exposure (in case-con-
trol studies) or outcome of interest (for cohort studies) of 
non-randomised studies.
AnAlysIs plAn
All analyses will be carried out in Stata, R and Matlab.
Meta-analysis of differences in risk between AdHd and 
controls
ORs will be calculated from the reported data if they 
cannot be directly extracted. OR and HR above 1 will indi-
cate a higher risk of unintentional injuries in the ADHD 
population compared with the non-ADHD groups. All 
valid outcomes from articles will be included in a single 
database. These will include any unadjusted or adjusted 
OR or HR which would fulfil independently the inclu-
sion criteria of our meta-analysis. Multiple valid outcomes 
within the same report are expected, often due to studies 
using different diagnosis strategies, reporting results 
in subgroups or including different valid treatment 
settings. This database will also encode other continuous 
or dichotomous (dummies) variables of interest for the 
meta-regression and subgroup analyses.
If an article reports two separates studies they will be 
considered independent, and conversely, if two articles 
report results on the same data or database they will be 
considered as multiple outcomes from the same study.
Heterogeneity and small sample bias
Q-Cochran’s53 and the I2 index54 will be used to evaluate 
heterogeneity between studies. Cochran’s Q is calculated 
as the weighted sum of squared differences between 
individual study effects and the meta-analytic estimate. 
Weights are the same as in the meta-analysis (basically 
sample sizes), and hence, this measure is known to 
have low power when there are few and small studies. 
Conversely, the test has excessive power with many or 
big studies. The I2 index is a newer, complementary 
measure that describes the percentage of total variation 
across studies that is due to heterogeneity, and it does not 
depend on the number of studies considered. The higher 
the l2 value the higher the heterogeneity in the results, 
with values >50% indicating substantial heterogeneity.
Begg’s adjusted rank correlation test55 will be used to 
formally assess the presence of ‘small-sample’ bias (which 
encompasses publication bias); an approach that will be 
combined with the use of funnel plots for a qualitative 
visual analysis, and statistical testing of asymmetry.56
A single effect size will be used per study to calculate 
the degree of between-study heterogeneity and the risk 
of small-sample bias. The most general and statistically 
controlled outcome per study will be used. If there is 
more than one possible outcome fulfilling these criteria, 
it will be chosen at random from the available outcomes.
dependency among outcomes
Effect sizes are assumed independent in standard 
meta-analytical procedures. A common way to deal with 
the non-independence of outcomes has been to compute 
a mean outcome and use the study-level combined 
measure in the meta-analysis,57 but this approach leaves 
out potentially relevant information. A recent alterna-
tive is Robust Variance Estimation (RVE), a statistical 
technique that models the nested structure between 
outcomes of the same study.58 RVE empirically estimates 
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the sampling variance in a way that is robust to misspeci-
fication of the weights and regarding the assumptions on 
distributions of the effect. Estimation of the meta-analytic 
parameters through RVE is adequate for dichotomous 
outcomes when enough studies are included.59 60 More-
over, RVE has been shown to produce similarly unbiased 
results to other, more complex, methods of dealing with 
multiple outcomes and it is more efficient than averaging 
effects within studies.61 A main advantage compared with 
other methods is that it does not require to have infor-
mation on the covariance structure of the effect sizes, an 
information that is typically hard to acquire.
Whereas this method yields valid results regard-
less of the weights used, a strategy using approximate 
inverse-variance weights has been proposed for effi-
ciency purposes: a random-effects model with variation 
of effect sizes between studies (τ2) and equicorrelation 
(p) between same-study effect sizes (I2) is assumed.58 
This strategy is efficient to estimate a mean model from 
outcomes which are typically correlated at the study 
level, but are usually independent between studies. We 
will use p=0.8, similarly to previous studies,62 but these 
same studies and simulations by the RVE authors have 
shown little change with different values of p.63 More-
over, a sensitivity analysis with varying levels of p can be 
carried out to check the influence of such decision.58 
RVE has been implemented in Stata and R and there 
are published guidelines for it.64 65 This implementation 
includes an improved estimation for small samples.66 We 
will use RVE for the inference of a mean effect size and 
meta-regression analyses. Regarding meta-regression, 
as df are obtained from the number of studies (instead 
of outcomes) and variables are likely to be correlated, 
it will be performed separately for each variable (bivar-
iate regressions). RVE distinguishes between interstudy 
effects (variability due to factors that change at the 
study level but are maintained for different outcomes) 
and intrastudy effects (variability due to factors that 
change at the outcome level). An example of the former 
would be publication date, and an example of the latter 
would be sex in the case of those studies that report ORs 
separately for boys and girls. It must be noted however, 
that factor can vary both interstudies and intrastudies, 
for example, mean age also changes between studies.
Mean effect sizes
We will first calculate a population-average effect size 
(ORs and HRs separately) through the combination 
of the most general and better statistically controlled 
outcome per study. If there is more than one possible 
outcome fulfilling these criteria they will all be included 
in the analysis.
Initial sensitivity analyses for this average effect size will 
be: 1) to vary in 0.1 steps the p correlation parameter, 
2) to compare articles with a follow-up of a year or less 
to articles with a longer follow-up (including variable 
follow-ups). Since an individual can have more than one 
injury along their life, but only dichotomous outcomes 
are considered, different observation periods could 
modify differences between groups.
Additional sensitivity analyses will derive from the variety 
of designs accepted and the definitions of patients and 
controls. Data will be reanalysed excluding case-control 
studies (comparing injured vs non-injured individuals). 
Similarly, an analysis only using the most stringent defini-
tions of ADHD (DSM, ICD, registry or clinical history) and 
controls (excluding studies with clinical control groups) will 
be carried out. Studies in which injuries are self-reported 
will be eliminated in another analysis. Risk of bias (number 
of stars in the Newcastle-Ottawa Scale) will be considered a 
continuous variable and its effect evaluated. A final analysis 
will compare the effect size of studies in which data were 
acquired before and after the year 2000.
Two other population average models will be obtained 
by 1) computing a mean effect size only including unad-
justed OR and 2) computing a mean effect size only 
including adjusted OR.
Effect sizes whose 95% CIs do not cover zero will be 
considered significant. All the effects described in this 
section are interstudy.
subgroup analyses and meta-regression
We will also assess, if feasible, the moderating role of 
clinical and design variables at the intrastudy and inter-
study levels. The former include gender, age, comorbidity 
(mainly ODD and CD), medication status and preva-
lence of ADHD, whereas the latter includes the setting 
of treatment. The data to be used in these analyses will 
include any outcome which would independently fulfil 
the inclusion criteria as long as they differ in something 
else than the statistical model used to obtain them: If 
there is more than one statistical model for the same 
data, the outcome derived from the model controlling 
for more covariates will be used. Percentage of medicated 
patients, age (ideally the mean or median of the whole 
group, otherwise midpoint in the interval of ages) and 
prevalence of ADHD (percentage of ADHD that a given 
diagnostic strategy yields in a cohort) will be included as 
continuous variables and their effect estimated through 
meta-regression. We will also explore the feasibility of 
conducting the following subgroup analyses: 1) male vs 
female participants, 2) three age groups (4–8, 9–13 and 
14–17 years), 3) clinical setting (physician office visits, 
emergency department visit and hospitalisation). In all 
these cases, differences between groups will be statistically 
tested (p<0.05 will be considered significant). In the case 
of sex, intrastudy outcomes reported only in males will 
be compared with outcomes of studies in which ORs are 
reported for both boys and girls, and the same will be 
done for outcomes in females.
The evaluation of the effect of comorbidity is important 
in our meta-analysis, but such an effect is difficult to meta-
analyse since studies handle it very differently. We are 
especially interested in disentangling the effect ODD and 
CD from that of ADHD. We will compare outcomes from 
studies in which the rate of ODD/CD is not controlled to 
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those in which the presence of ODD or CD is controlled 
in the patient sample by design (excluding subjects with 
ODD or CD) or statistically, and to those in which all 
patients have comorbidity with these disorders. If feasible, 
a similar analysis including any other comorbidities will be 
executed.
Sensitivity and meta-regression analyses will be carried 
out only for the combination of ORs, as we do not expect 
enough studies to carry out this kind of analyses for the 
combination of HRs.
Meta-analysis on the effect of medication
The second objective of the present project will be to 
assess the medication effect in the probability of non-in-
tentional injuries occurrence. For this purpose, the 
chosen measure of association will be the IRR. Heteroge-
neity and presence of ‘small-sample’ bias will be evaluated 
as in the first meta-analysis.
A generalised linear mixed model using the Poisson 
distribution with the log link function will be imple-
mented.67 Specifically, since it is expected that a small 
number of studies will be included in this meta-anal-
ysis, a fixed effects Poisson regression model will be 
carried out. In this model, the dependent variable is 
set as the logarithm of the total number of counts, the 
logarithm of the person-time is included as an offset 
and the medication is included as an explanatory vari-
able. Additionally, the model incorporates dummy vari-
ables as study-specific fixed effects, in order to preserve 
the within studies comparison of medicated versus 
non-medicated groups.
Sensitivity analyses will be performed based on the 
exclusion of studies which do not implement a self-con-
trolled case series design.
plAnned ContrIbutIons to tHe MetA-AnAlysIs
The tasks regarding the systematic review and the meta-anal-
ysis will be as follows: MRG and GA will conduct searches, 
screen papers and retain those that fulfil inclusion criteria. 
SC will arbitrate discrepancies between these researchers 
regarding article inclusion. MRG GA, NA, SM, EL and 
PdCM will read the included papers and extract the data. 
MAS, GA, MRG and SC will carry out the statistical analysis. 
PdCM, SC and CS will provide expertise on issues related to 
child and adolescent psychiatry and results interpretation/
implications. GA and MR will draft the article discussing the 
results and SC and CS will further edit it. All collaborators 
will approve the final article.
etHICAl ConsIderAtIons And dIsseMInAtIon plAns
No ethical issues are predicted. All the authors will 
declare if they have any competing conflict of interest. 
The results will be published in a peer-reviewed journal 
and presented at national and international conferences 
of psychiatry, psychology, paediatrics and traumatology.
regIstrAtIon And stAtus
Before data extraction completion, the protocol of this 
meta-analysis was registered in PROSPERO, an interna-
tional register of protocols for health-related systematic 
reviews supported by the National Institute of Health 
Research (NIHR) and maintained by the University 
of York (UK). Registration date: 8 May 2017, protocol 
number CRD42017064967. Writing of the protocol and 
preliminary searches started by June 2016. Data piloting 
commenced in September 2016. Data extraction started 
in December 2016 an ended in August 2017. Data analysis 
is estimated to end by August 2017.
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